Additional Table 2. Characteristics of the pediatric patients with standard VDZ protocol and enhancement protocol

		Standard protocol (N=29)	Enhancement protocol (N=21)
Age at diagnosis, years, median (range)		11.0 (3.2-16.1)	12.4 (3.8-15.5)
Age at start of VDZ, median (range)		15.1 (7.6-19.1)	14.8 (4.6-15.6)
Disease duration, years, median (range)		4 (0.4-12.6)	2.3 (0.3-10.6)
Disease type	Crohn's disease N (%) Ulcerative colitis N (%) IBD-U N (%)	9 (31) 8 (28) 12 (41)	5 (24) 9 (43) 7 (33)
Location CD, n (%)	L1 distal 1/3 ileum ± cecal disease L2 colitis L3 ileocolitis L3+L4a upper disease	0 1 (11) 5 (56)) 3 (33)	0 2 (40) 1 (20) 2 (40)
Behaviour CD, n (%)	B1 non structuring, non penetrating B2 stricturing B3 penetrating	7 (78) 1 (11) 1 (11)	3 (60) 1 (20) 1 (20)
Perianal disease n (%)		1 (11)	2 (40)
Location UC/IBD-U n (%)	E1 proctitis E2 left-sided E3 extensive E4 pancolitis	1 (5) 4 (20) 3 (15) 12 (60)	0 (0) 3 (19) 3 (19) 10 (62)
Severity n (%)	S1 ever severe	20 (100)	16 (100)
Growth delay n (%)		9 (31)	6 (29)
Surgery n (%)		2 (7)	1 (5)
Prior biologic medication n (%)	Biologic-naïve TNF-α naïve Exposure for ustekinumab	9 (31) 9 (31) 2 (7)	3 (14) 4 (19) 3 (14)

Medication at vedolizumab induction n (%)	TNF-blocker Azathioprine Methotrexate 5-ASA Corticosteroid	20 (69) 3 (10) 3 (10) 17 (59) 24 (83)	21 (100) 3 (14) 0 (0) 10 (48) 18 (86)
Fecal calprotectin at vedolizumab induction median μg/g (25-75% interquartile) < 100 μg/g >1000 μg/g		781 (492-1721) 3 (10) 9 (31)	684 (130-1251) 1 (5) 7 (33)